Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume

Savara Inc (NASDAQ:SVRA) shares saw unusually-strong trading volume on Wednesday . Approximately 6,053,835 shares changed hands during mid-day trading, an increase of 388% from the previous session’s volume of 1,240,750 shares.The stock last traded at $4.11 and had previously closed at $4.14.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SVRA. JMP Securities decreased their target price on Savara from $10.00 to $9.00 and set a “market outperform” rating on the stock in a report on Tuesday. Oppenheimer increased their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. HC Wainwright lifted their target price on shares of Savara from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Evercore ISI lowered their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. Finally, Guggenheim boosted their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Savara currently has an average rating of “Buy” and an average price target of $11.17.

Savara Price Performance

The company has a market capitalization of $591.45 million, a P/E ratio of -11.19 and a beta of 1.00. The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. The company’s fifty day moving average price is $4.28 and its 200 day moving average price is $4.61.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, sell-side analysts forecast that Savara Inc will post -0.41 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently made changes to their positions in SVRA. DRW Securities LLC bought a new stake in Savara during the 2nd quarter worth $62,000. Profund Advisors LLC bought a new position in Savara in the 2nd quarter valued at approximately $105,000. XTX Topco Ltd boosted its position in Savara by 289.1% during the 2nd quarter. XTX Topco Ltd now owns 41,059 shares of the company’s stock worth $165,000 after buying an additional 30,508 shares during the period. ClariVest Asset Management LLC increased its position in Savara by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company’s stock valued at $1,034,000 after acquiring an additional 7,170 shares during the period. Finally, Choreo LLC bought a new position in shares of Savara during the second quarter valued at $59,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.